Why Is SCHOLAR ROCK HLDG CO (SRRK) Stock Moving Today?

Why SRRK stock is up today

SRRK stock rose 6.31% to $51.20 in morning trading on Thursday, driven primarily by a price target increase from JPMorgan. The firm raised its price target to $70 from $63, signaling optimism about the company's product launch prospects. The move comes amid broader market speculation around the biotech and weight-loss drug sectors, though no earnings report or major partnership announcement was issued by Scholar Rock.

What Happened

JPMorgan analysts adjusted their outlook for SRRK, raising the price target to $70 per share. This upgrade was cited in multiple reports and appears to have directly influenced the stock's performance. In addition, the company announced new employee inducement grants under Nasdaq Listing Rule 5635(c)(4). These include options covering 23,801 shares with a $51.85 exercise price and 59,301 restricted stock units that vest over four annual installments, subject to continued service. The grants suggest ongoing efforts to retain and incentivize key personnel.

Retail traders and investors are also showing increased interest in the stock, with SRRK trading higher by more than 12% in premarket activity. This follows recent news that Scholar Rock has reached a "defining moment" with its first muscle-targeted treatment for spinal muscular atrophy.

What The Data Shows

The stock opened at $48.38 and reached an intraday high of $51.40 at 10:05 AM ET. Volume has reached 0.6 million shares, which is 0.4 times the 3-month daily average. Over the last eight trading sessions, the stock has fallen 15.1% from $55.67 to $47.26. Insider transactions in the last 90 days show 5 sales totaling $923K, with no insider purchases recorded. The stock is currently trading within its 52-week range of $27.07 to $61.76.

What To Watch

SRRK has no upcoming earnings report scheduled. Investors should monitor the breadth of analyst coverage and whether other firms follow JPMorgan's lead in upgrading the stock.